Stratec SE buy melinda
Start price
17.11.17
/
50%
€64.00
Target price
20.11.17
€65.50
Performance (%)
2.73%
End price
20.11.17
€65.75
Summary
This prediction ended on 20.11.17 with a price of €65.75. With a performance of 2.73%, the BUY prediction by melinda for Stratec SE closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Stratec SE | -2.851% | -2.851% | -11.435% | -70.334% |
iShares Core DAX® | -1.414% | 7.218% | 17.151% | 15.732% |
iShares Nasdaq 100 | -2.316% | 4.450% | 18.360% | 30.945% |
iShares Nikkei 225® | -2.756% | 10.071% | 10.704% | 2.733% |
iShares S&P 500 | -1.849% | 4.760% | 19.639% | 34.852% |
According to melinda what are the pros and cons of Stratec SE for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Stratec Biomedical AG diskutieren
SecteurEquipement und moderne medizinische Technologie Präsentation Agenda 28/11
STRATEC Biomedical AG, die in der Konstruktion und Herstellung von automatisierten Analysensystemen auf dem Gebiet der klinischen Diagnose und biotechnology.It betreibt durch die folgenden Segmente: Instrumentation, Diatron, Verbrauchsmaterial und alle other.The Instrumentation Segment Bezieht sich auf das Design und
(Zielkurs erreicht)
Stopped prediction by melinda for Stratec SE
Stratec SE
Start price
Target price
Perf. (%)
€122.40
30.12.20
30.12.20
€128.00
30.12.21
30.12.21
12.75%
31.12.21
31.12.21
Could be worthwhile Investment >10% per year